Edition:
United Kingdom

PAION AG (PA8G.DE)

PA8G.DE on Xetra

2.60EUR
19 Jan 2018
Change (% chg)

€0.01 (+0.39%)
Prev Close
€2.59
Open
€2.56
Day's High
€2.61
Day's Low
€2.56
Volume
34,371
Avg. Vol
139,937
52-wk High
€3.53
52-wk Low
€2.15

Select another date:

Mon, Dec 18 2017

BRIEF-PAION Grants Exclusive License To Mundipharma For Development And Commercialization Of Remimazolam In Japan

* SAID ON SUNDAY GRANTED EXCLUSIVE LICENSE TO MUNDIPHARMA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN JAPAN

BRIEF-PAION announces clinical development progress with remimazolam

* DGAP-NEWS: PAION ANNOUNCES CLINICAL DEVELOPMENT PROGRESS WITH REMIMAZOLAM BY ITS PARTNER HANA PHARM IN SOUTH KOREA

BRIEF-PAION: FDA considers current human abuse liability program with remimazolam in U.S. as sufficient

* ‍FDA CONSIDERS CURRENT HUMAN ABUSE LIABILITY PROGRAM WITH REMIMAZOLAM IN U.S. AS SUFFICIENT

BRIEF-PAION ‍9-mth net loss at 8.5 mln euros

* DGAP-NEWS: PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2017

BRIEF-Paion: Japan patent office grants dosing patent for remimazolam

* DGAP-NEWS: PAION AG: JAPAN PATENT OFFICE GRANTS DOSING PATENT FOR REMIMAZOLAM IN JAPAN

BRIEF-PAION granted formulation patent for remimazolam in the EU

* DGAP-NEWS: PAION AG: EUROPEAN PATENT OFFICE GRANTS FORMULATION PATENT FOR REMIMAZOLAM IN THE EU

BRIEF-Paion H1 net loss narrows to 5.8 million euros

* ‍NET LOSS FOR FIRST HALF-YEAR 2017 WAS EUR 5.8 MILLION COMPARED TO A NET LOSS OF EUR 13.2 MILLION IN PRIOR-YEAR PERIOD​

BRIEF-Paion: Rr-Pharm starts phase III trial in general anesthesia​

* DGAP-NEWS: PAION ANNOUNCES CLINICAL DEVELOPMENT PROGRESS WITH REMIMAZOLAM BY ITS PARTNER R-PHARM IN RUSSIA

Select another date: